← All trials
NCT05457933
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2022
- Primary completion
- Dec 30, 2022
- Completion date
- Mar 30, 2023
- First posted
- Jul 14, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medanta - The MedicityLead sponsor
- Medanta - The MedicityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.